JAMA Otolaryngology–Head & Neck Surgery· 2026Q1
Newborn Hearing Screening in the Otoferlin Gene Therapy Era
- 0citations
- Q1SCImago
- 2026year
Short summary
This Viewpoint advocates for updating newborn hearing screening protocols to incorporate automated auditory brainstem response (AABR) testing for otoferlin (OTOF) gene therapy candidacy.
AI-generated from the title and abstract; the full text is not read.
Key points
- Current newborn hearing screening may not adequately identify candidates for OTOF gene therapy.
- Automated auditory brainstem response (AABR) testing is proposed as a key diagnostic tool.
- Updated screening recommendations are needed to facilitate early OTOF gene therapy intervention.
- This approach could improve outcomes for infants with OTOF-related hearing loss.
AI-generated from the title and abstract; the full text is not read.
Abstract
The Viewpoint advocates for updates to newborn hearing screening recommendations to include automated auditory brainstem response testing to determine candidacy for otoferlin ( OTOF ) gene therapy.
The authors' abstract, as published at the source. JAMA Otolaryngology–Head & Neck Surgery, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Sensory Systems
Sensory SystemsNeuroscience